Global Sarcoma Therapy Now Available in Thailand

Resumen detallado

Independent biopharmaceutical company Specialised Therapeutics announced that the Thailand Food and Drug Administration approved YONDELIS® (trabectedin) on 24 July 2026 for the treatment of adult patients with advanced soft tissue sarcoma (STS).1

SINGAPORE, Nov. 15, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics announced that the Thailand Food and Drug Administration approved YONDELIS® (trabectedin) on 24 July 2026 for the treatment of adult patients with advanced soft tissue sarcoma (STS).1

The regulatory approval grants access to YONDELIS for patients who have failed prior treatment with anthracyclines and ifosfamide, or for those who are unsuited to receive these agents.1 The approval is based on the clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine in patients with unresectable or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline and at least one additional chemotherapy regimen.2,3

In the pivotal Phase 3 clinical trial, patients treated with YONDELIS achieved a statistically significant improvement in median progression-free survival (PFS) of 4.2 months versus 1.5 months for trabectedin vs dacarbazine HR, 0.55; p

YONDELIS demonstrated a manageable safety profile, with severe (Grade 3 or 4) adverse reactions occurring in less than one-third of patients. The most common adverse reactions of any severity grade included neutropenia, nausea, vomiting, elevated liver enzymes (AST/ALT), anaemia, fatigue, thrombocytopenia, decreased appetite, and diarrhoea.1,2

YONDELIS is an established antineoplastic agent originally derived from the sea squirt (Ecteinascidia turbinata). It exerts the anti-tumor effect by binding to the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from multiplying.4

STS is a rare and complex disease. In Thailand, the age-standardized incidence rate of STS is 2.14 per 100,000 person-years, which is relatively low compared to Western nations.

"The approval of YONDELIS in Thailand expands access to a recognized, international standard-of-care therapy for patients living with…

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.